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TO THE EDITOR:
In cystic fibrosis (CF), an inherited disease, progressive 
lung destruction, triggered by chronic pulmonary infection 
with opportunistic pathogens, such as Pseudomonas 
aeruginosa, is the leading cause of premature death. 
Consequently, there is a strong incentive for early 
detection and eradication of P. aeruginosa infection. 
Monitoring lower airway (LAW) colonization and using 
targeted therapy is the current international standard, 
which is considered to provide better chances to eradicate 
the pathogen before it changes to a mucoid phenotype 
and forms biofilms, which then makes eradication nearly 
impossible. However, eradication of a novel P. aeruginosa 
colonization is challenging, and success rates vary widely 
(60-90%)(1-3) in divergent protocols consisting of the 
sole use of inhaled antibiotics, such as tobramycin or 
colomycin, for periods of about one to six months, or 
combining oral ciprofloxacin with intravenous antibiotics.
In the last years, the importance of the upper airways 
(UAW) and the paranasal sinuses for eradication success 
has been recognized because they are sites for pathogen 
acquisition, pathogen persistence, LAW contamination, 
and cross-infection.(4-7) In this context, we implemented 
routine UAW monitoring by nasal lavage performed every 
three months as a standard procedure at the CF Center 
in the University of Jena, in the city of Jena, Germany. 
Thereby, we previously identified CF patients with 
primary isolated sinonasal P. aeruginosa colonization and 
we found that identical P. aeruginosa strains persisted 
in the UAW of CF patients after lung transplantation, 
initially pseudomonas-free transplanted lungs having 
been colonized with those strains.(8) In addition, we 
proved that 96% of the detected P. aeruginosa strains 
were genetically identical in both UAW and LAW of CF 
patients chronically colonized with that pathogen, which 
underscores the ”united airway” concept.(8)
Here, we demonstrate that periodic and close monitoring 
of LAW and UAW colonization and the use of an aggressive 
treatment regimen resulted in successful and longstanding 
eradication of P. aeruginosa in a 13-year-old male patient 
with CF (homozygous F508del genotype). In November 
of 2011, when the patient was 6 years old, his first P. 
aeruginosa colonization was identified by means of a 
routine deep throat swab. Subsequently, in accordance 
with our standard protocol for intermittent colonization, the 
patient was monthly monitored for UAW colonization (nasal 
lavage with 10 mL of isotonic saline per nostril) and LAW 
colonization (deep throat swabs or sputum collection). (8) 
After detection of the first P. aeruginosa colonization, the 
father of the patient meticulously documented all culture 
results and treatments and demanded more efficient 
therapeutic approaches at every new isolation of the 
pathogen. Knowing the common standards of therapy, 
we decided to gradually adapt our approach towards an 
aggressive eradication regimen with oral or intravenous 
antibiotics together with inhaled antibiotic therapy. The 
standard procedure with oral ciprofloxacin and inhaled 
colistin failed to eradicate P. aeruginosa from the LAW 
(Figure 1), and, five months later, the pathogen was 
detected in the UAW and LAW. Therefore, we extended 
the therapy by including quarterly i.v. cycles with 
ceftazidime and tobramycin and permanent treatment 
with oral azithromycin. The patients also received colistin 
by nasal nebulization via a pulsating aerosol nebulizer 
(PARI SINUS™; PARI GmbH, Starnberg, Germany).(9) 
This approach was proven to deliver aerosols into the 
paranasal sinuses by a superimposed vibration of 43 Hz, 
applied during periods of breath holding. In contrast, 
conventional nebulization through the nose was shown 
not to deliver relevant amounts of nebulized drugs to the 
sinuses.(10) With the continued intermittent detection of 
P. aeruginosa in both airway compartments, an off-label 
eradication regimen, consisting of simultaneous inhaled 
aztreonam for the UAW and LAW, alternated monthly with 
inhaled tobramycin, was implemented. Subsequently, 
after nine positive P. aeruginosa cultures from the LAW 
and three from the UAW, P. aeruginosa was eradicated 
in January of 2013, as confirmed by negative cultures 
from UAW and LAW samples collected every month 
thereafter. In addition, IgG antibody titers related to the 
pathogen (alkaline protease, elastase, and exotoxin A) 
remained negative, as they had been before and during 
the detection of P. aeruginosa in UAW and LAW, in control 
samples routinely taken every year. At this writing, the 
patient has remained free of the colonization for more 
than 72 months, which allowed the therapeutic burden 
to be reduced to a minimum. 
Our experience has shown that additional routine 
sampling of UAW can reveal early sinonasal colonization, 
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Figure 1. Monitoring of upper and lower airway colonization and therapeutic regimens for Pseudomonas aeruginosa (PSA) eradication. b.i.d.: twice a day; t.i.d.: three times a day; neg.: 
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which, if unrecognized, most probably would have 
prevented the successful eradication of the pathogen. 
Monthly sampling detected intermittent colonization and 
later confirmed complete elimination of P. aeruginosa. 
Neither would have been possible if we had followed 
international standards for CF care, which only 
recommend LAW sampling 2-4 times/year. The use of 
inhaled antibiotics alone is likely to fail UAW treatment. 
This corroborates the findings of a group of authors(5) 
who showed that if P. aeruginosa is not eradicated 
from the entire airway system, it can undergo evolution 
and diversification processes in order to adapt to the 
immune system of the host in the paranasal sinuses. If 
the paranasal sinuses are not considered as a possible 
reservoir for P. aeruginosa, after the cessation of an 
inhaled therapy alone, the pathogen may descend to 
the lungs and cause a new pulmonary colonization 
that can be even more virulent.
No side effects were reported during the off-label 
eradication regimen. However, the daily burden of 
treatment widely exceeded the regular number of 
inhalations in CF patients. Nevertheless, our patient 
has been free of colonization for 6 years, during which 
the therapeutic burden could be reduced to a minimum. 
We show here that the eradication of persistent P. 
aeruginosa is possible with a consistent therapeutic 
regimen that, in this case, was strongly promoted by 
the insistence of the family. This may have contributed 
to a relevantly improved prognosis of the pulmonary 
function and, thereby, life expectancy of the patient. 
Based on our experience, we recommend repeated 
microbiological assessment of both UAW and LAW, 
especially in patients with intermittent P. aeruginosa 
colonization.(6) Consequently, such an approach should 
also be included in future studies on P. aeruginosa 
eradication in CF patients.
ACKNOWLEDGMENTS
The whole process was closely administered and 
monitored by the father of the patient. We want to 
thank him and the entire family for their commitment. 
Mr. Mainz received fees for lectures from PARI GmbH 
and Vertex GmbH.
REFERENCES
1. Blanchard AC, Horton E, Stanojevic S, Taylor L, Waters V, Ratjen F. 
Effectiveness of a stepwise Pseudomonas aeruginosa eradication 
protocol in children with cystic fibrosis. J Cyst Fibros. 2017;16(3):395-
400. https://doi.org/10.1016/j.jcf.2017.01.007
2. Ratjen F, Munck A, Kho P, Angyalosi G. Treatment of early 
Pseudomonas aeruginosa infection in patients with cystic fibrosis: 
the ELITE trial. Thorax. 2010;65(4):286-91. https://doi.org/10.1136/
thx.2009.121657
3. Proesmans M, Vermeulen F, Boulanger L, Verhaegen J, De 
Boeck K. Comparison of two treatment regimens for eradication 
of Pseudomonas aeruginosa infection in children with cystic 
fibrosis. J Cyst Fibros. 2013;12(1):29-34. https://doi.org/10.1016/j.
jcf.2012.06.001
4. Mainz JG, Hentschel J, Schien C, Cramer N, Pfister W, Beck JF, 
et al. Sinonasal persistence of Pseudomonas aeruginosa after 
lung transplantation. J Cyst Fibros. 2012;11(2):158-61. https://doi.
org/10.1016/j.jcf.2011.10.009
5. Hansen SK, Rau MH, Johansen HK, Ciofu O, Jelsbak L, Yang L, 
et al. Evolution and diversification of Pseudomonas aeruginosa in 
the paranasal sinuses of cystic fibrosis children have implications 
for chronic lung infection. ISME J. 2012;6(1):31-45. https://doi.
org/10.1038/ismej.2011.83
6. Aanæs K. Bacterial sinusitis can be a focus for initial lung colonisation 
and chronic lung infection in patients with cystic fibrosis. J Cyst 
Fibros. 2013;12 Suppl 2:S1-20. https://doi.org/10.1016/S1569-
1993(13)00150-1
7. Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Høiby N, et al. 
Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: 
an evolutionary perspective. Nat Rev Microbiol. 2012;10(12):841-51. 
https://doi.org/10.1038/nrmicro2907
8. Mainz JG, Naehrlich L, Schien M, Kading M, Schiller I, Mayr S, et al. 
Concordant genotype of upper and lower airways P aeruginosa and S 
aureus isolates in cystic fibrosis. Thorax. 2009;64(6):535-40. https://
doi.org/10.1136/thx.2008.104711
9. Mainz JG, Schädlich K, Schien C, Michl R, Schelhorn-Neise P, 
Koitschev A, et al. Sinonasal inhalation of tobramycin vibrating 
aerosol in cystic fibrosis patients with upper airway Pseudomonas 
aeruginosa colonization: results of a randomized, double-blind, 
placebo-controlled pilot study. Drug Des Devel Ther. 2014;8:209-17. 
https://doi.org/10.2147/DDDT.S54064
10. Moller W, Saba GK, Haussinger K, Becker S, Keller M, Schuschnig U. 
Nasally inhaled pulsating aerosols: lung, sinus and nose deposition. 
Rhinology. 2011;49(3):286-91. https://doi.org/10.1164/ajrccm-
conference.2011.183.1_MeetingAbstracts.A4432
J Bras Pneumol. 2019;45(6):e20190191 3/3
